Catalog Home Page

Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze

Kõks, S., Soosaar, A., Võikar, V., Volke, V., Ustav, M., Männistö, P.T., Bourin, M. and Vasar, E. (1998) Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides, 32 (3). pp. 235-240.

Link to Published Version: https://doi.org/10.1016/S0143-4179(98)90042-7
*Subscription may be required

Abstract

This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 μg/kg) and a selective CCKB receptor agonist BOC-CCK-4 (1, 10 and 50 μg/kg) induced a dose-dependent anxiogenic-like action in the plus-maze model of anxiety. BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was mediated via CCKB receptor subtype. The opioid antagonist naloxone itself (0.5 mg/kg) did not change the exploratory activity of rats in the plus-maze. However, the combination of naloxone with the sub-effective doses of caerulein (1 μg/kg) and BOC-CCK-4 (1 μg/kg) induced a significant inhibition of exploratory behaviour in rats. Accordingly, CCK and endogenous opioid peptides have an antagonistic role in the exploratory model of anxiety in rats.

Item Type: Journal Article
Publisher: Elsevier
Copyright: © 1998 Elsevier Ltd.
URI: http://researchrepository.murdoch.edu.au/id/eprint/53009
Item Control Page Item Control Page